Biosimilars-focused Coherus debuts with Daiichi deal

Biosimilars company Coherus BioSciences Inc. (Redwood City, Calif.) made its public debut Monday and announced a deal with Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) to exclusively develop and commercialize biosimilars of autoimmune drugs etanercept and rituximab in Asia. The partners will develop and manufacture the biosimilars, while Daiichi will commercialize the products in Japan, South Korea and Taiwan. Coherus retains rights to develop and commercialize the biosimilars outside of these territories. Sagent Advisors advised Coherus. Financial details were not disclosed. ...